COST-EFFECTIVENESS OF SYSTEMATIC SCREENING AND TREATMENT OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) IN UNITED STATES

被引：0
|
作者：
Lau, Anson Tsz Chun [1 ]
DiDomenico, Robert J., Jr. [1 ]
Kim, Kibum [1 ]
机构：
[1] Univ Illinois, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2023年 / 81卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1106-003
引用
收藏
页码：400 / 400
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Liu, Chia-Liang
    Bellows, Brandon K.
    Hernandez, Inmaculada
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Kazi, Dhruv S.
    JAMA NETWORK OPEN, 2021, 4 (07) : E2114501
  • [32] COST-EFFECTIVENESS OF DAPAGLIFLOZIN FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION: ANALYSES FROM THE PERSPECTIVES OF FRANCE AND THE UNITED STATES
    Binnie, R.
    Omar, Alsaleh Aj
    VALUE IN HEALTH, 2022, 25 (01) : S60 - S60
  • [33] PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF EMPAGLIFLOZIN (JARDIANCE®) IN THE TREATMENT OF PATIENTS WITH HEART FAILURE (HF) WITH PRESERVED EJECTION FRACTION (HFPEF) IN FRANCE, BASED ON EMPEROR-PRESERVED CLINICAL TRIAL
    Levy, P.
    Lamblin, N.
    Groyer, H.
    Chollet, J.
    Tardu, J.
    Linden, S.
    Fauchier, L.
    VALUE IN HEALTH, 2022, 25 (12) : S83 - S83
  • [34] Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States
    Nechi, Regina Nwamaka
    Rane, Amey
    Karaye, Rukayyah M.
    Ndikumukiza, Cyrille
    Alsahali, Saud
    Jatau, Abubakar I.
    Zoni, Cesar Rodrigo
    Alanzi, Abdullah
    Karaye, Ibraheem M.
    Yunusa, Ismaeel
    CLINICAL THERAPEUTICS, 2023, 45 (07) : 627 - 632
  • [35] Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction (Aug, 10.1001/jamacardio.2021.3070, 2021)
    AbouEzzeddine, O. F.
    Davies, D. R.
    Scott, C. G.
    JAMA CARDIOLOGY, 2021, 6 (12) : 1469 - 1469
  • [36] Validation of two simple scores to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction
    Llevadot Sesmilo, M.
    Cediel, G.
    Domingo, M.
    Santesmases, J.
    Moragas, G.
    Sola, M.
    Garcia-Calvo, X.
    Guix, G.
    Santiago-Vacas, E.
    Borrellas, A.
    Codina, P.
    Ruiz-Cueto, M.
    Camblor, A.
    Lupon, J.
    Bayes-Genis, A.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [37] A SYSTEMATIC REVIEW ON THE EFFICACY OF PHARMACOLOGICAL TREATMENTS IN PATIENTS WITH HEART FAILURE (HF) WITH PRESERVED EJECTION FRACTION (HFPEF)
    Agrawal, R.
    Ahuja, A.
    Thakur, L.
    Natani, H.
    Cristino, J.
    Croft, D.
    Gielen, V
    VALUE IN HEALTH, 2018, 21 : S95 - S95
  • [38] Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: A cost-effectiveness analysis
    Rane, Amey
    Nechi, Regina Nwamaka
    Imam, Maryam
    Zoni, Cesar Rodrigo
    Ndikumukiza, Cyrille
    Karaye, Ibraheem M.
    Yunusa, Ismaeel
    Alanzi, Abdullah
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (09): : 1045 - 1053
  • [39] SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study
    Lu, He
    Shang, Pingping
    Zhou, Dexing
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [40] Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction
    Tsutsui, Hiroyuki
    Sakamaki, Hiroyuki
    Momomura, Shin-ichi
    Sakata, Yasushi
    Kotobuki, Yutaro
    Linden, Stephan
    Idehara, Koki
    Nitta, Daisuke
    ESC HEART FAILURE, 2024, 11 (01): : 261 - 270
12345